SurModics signs licensing and development agreement with Roche and Genentech
SurModics, a provider of drug delivery and surface modification technologies, has signed a licensing and development agreement with Roche and Genentech, a wholly-owned member of the Roche Group.
Swiss drug developer Roche boosted its hostile tender offer for biotechnology pioneer Genentech Inc. to US$93 per share Friday, raising the total offer value to $45.7 billion, after its initial offer failed to pick up much support from shareholders.